Home | Business News | Browse by Publication | P | PR Newswire

Positive Synvisc Data Published by Cochrane Collaboration.

Article Excerpt
Results Reaffirm Efficacy of Viscosupplementation and Synvisc

CAMBRIDGE, Mass., May 5 /PRNewswire-FirstCall/ -- Genzyme Corp. announced today that a lengthy review examining the clinical benefits of Synvisc(R) (hylan G-F 20) and the class of viscosupplements to which it belongs has been published by the Cochrane Collaboration, an independent, international organization that disseminates systematic reviews of healthcare interventions and clinical trials data. Synvisc is the leading viscosupplementation product for the treatment of pain due to osteoarthritis of the knee in the U.S. and Canada, and one of the top products in this category in Europe. Since it is delivered locally, Synvisc avoids many of the associated side-effects of traditional non-steroidal anti-inflammatory drugs and COX-2 agents.

Using rigorous, objective methodology, the Cochrane Collaboration review concluded that the class of viscosupplements is superior to placebo and that several of the products have greater efficacy than steroid injections in treating pain associated with osteoarthritis of the knee. Viscosupplements are injectable products delivered locally that are comprised of hyaluronan (HA) and hyaluronan derivatives. The review also showed that considerable, positive differences were reported for Synvisc versus placebo in a number of clinical trials, including statistically significant and clinically meaningful robust improvements in pain, stiffness, and physical functioning for...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!